Our Company

Board Of Directors

Dr. Glynn Wilson | Chief Scientific Officer

Glynn brings an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals, Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals, and Founder, CEO, and Chairman of TapImmune Inc. for 12 years which became Marker Therapeutics through a merger. At TapImmune he licensed cancer vaccine technology platforms and established the clinical pipeline.

Brian John | Chief Executive Officer

For the past 20 years, Brian has been an investor and global advisor to companies around the globe. He is the Founder of a highly successful financial consulting firm specializing in assisting emerging growth companies primarily in the sub- $100 million space and has worked with hundreds of companies in dozens of countries over the last 25 years. He also serves on the board of directors of The Learning Center at the Els Center of Excellence–a school for children with autism in Jupiter, Florida.

Douglas McKinnon | Chief Financial Officer

Mr. McKinnon’s 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-level positions in both private and public sectors, including Chairman and CEO of an American-Stock-Exchange traded company, VP – Chief Administrative Officer of a $12-billion market cap NASDAQ-traded company for which the management team raised over $2.2 billion, CFO of several publicly-held US, Canadian and Australian companies, and CEO/CFO of various other private enterprises. As an entrepreneur, Mr. McKinnon has been involved in organizations ranging from start-up companies using venture capital funding to publicly traded institutional-backed companies. Additionally, Mr. McKinnon has extensive merger and acquisition, and turnaround experience Mr. McKinnon attended Texas Christian University for both his BBA and MBA. He worked for nine years as a CPA in the SEC and the oil and gas practice section and member of the O&G Technical Committee of Coopers & Lybrand (now PricewaterhouseCoopers).

Richard Miller | Director

Since 2000, Rich has managed a consulting firm that advises emerging growth companies. Over the last twenty years, Mr. Miller has provided strategic advice to hundreds of companies across diverse industries. He has assisted C Level executives with expanding, financing, and other challenges emerging companies face. Mr. Miller was the Co-Founder of Teeka Tan Suncare Products. Prior to the company’s sale, he was instrumental in the design and launch of a full line of boutique sun care products. He managed the deal from “concept to sale”. He is an advocate for school safety and local schools through his grassroots group My School Counts.

Dr. Skender Fani | Director

Dr. Fani is the Chairman of Otis Elevator-Austria, Heim GmbH, a substantial real estate company in Vienna, Austria, and Polster GmbH, a leading public relations and sports management company in Germany and Austria. He also serves as Chairman of LOOS Bar GmbH in Vienna, Austria. Dr. Fani is a corporate lawyer in Austria and throughout the E.U. specializing in sports, entertainment, and business law. For the past 40 years, he has represented numerous top sports and entertainment personalities throughout Europe. He has been the personal advisor to presidents and owners of Europe’s top soccer teams, including MAGNA-Vienna, FC Barcelona, AS Roma, and Red Bull-Salzburg. He is the past Chairman of Rapid-Vienna, one of Europe’s most prestigious and historic soccer clubs.

Dr. Hector Alila | Director

Hector brings 30 years of demonstrated scientific experience in product development and successful management leadership in the biopharmaceutical industry. He is the Founding President and Chief Executive Officer of Esperance Pharmaceutical Inc. (Houston, Texas). Esperance is a clinical-stage biopharmaceutical company that has successfully developed a novel targeted cancer therapeutics currently in clinical development. Prior to Esperance, he served as Senior Vice President of Drug Development at Protalex, Inc. (New Hope, PA), where he led the development of a drug currently in clinical trials for the treatment of autoimmune diseases. He was Vice President of Product Development at Cell Pathways, Inc. (Horsham, PA) where he was responsible for the development of cancer drugs. He was the Director of Biology/pharmacology at GeneMedicine, Inc. (The Woodlands, Texas), were led the product development of gene medicines. He also held several research, product development, and management positions at SmithKline Beecham Pharmaceuticals. He obtained his Ph.D. degree from Cornell University.

Nancy Torres Kaufman | Director

Nancy is the Chairman and CEO of Beacon Capital LLC, a New York family office, that recently relocated to Jupiter, Florida.

Nancy officially founded Beacon Capital as her family office and investment platform in 2010 with a focus on investing in life sciences businesses globally. She was endorsed by four high-net-worth groups with proprietary capital that invested alongside Beacon’s strategy. Nancy and the team are responsible for originating, underwriting, and strategy, including the timing of exit.

Nancy and the team have consistently followed an investment strategy of identifying and working with experienced, strong management teams with excellent track records and the knowledge and drive to develop life science breakthroughs. Beacon’s objective is to invest in and help to make successful companies at the forefront of research and development into innovative therapies and technologies for patients, thereby delivering superior returns to its investors.

Christopher Melton | Director

Chris Melton was a Senior Real Estate Equity Analyst at RREEF Funds in Chicago from 1995 to 1997. From 2000 to 2008, Mr. Melton was a Portfolio Manager for Kingdon Capital Management (“Kingdon”) in New York City, where he ran in excess of $1 Billion book in media, telecom, and Japanese investment. Mr. Melton opened Kingdon’s office in Japan, where he set up a Japanese research company. From 1997 to 2000, Mr. Melton served as a Vice President at JPMorgan Investment Management as an equity research analyst, where he helped manage $ 1 Billion plus in REIT funds under management. Mr. Melton is the Principal and co-founder of Callegro Investments, a specialist land investor. He currently serves on several Public and Private Boards as well as Chairman of the Audit Committee of a NASDAQ listed company.

Gary Herman | Director

Mr. Herman is a seasoned investor with many years of investment and business experience. Since 2005, Mr. Herman has managed Strategic Turnaround Equity Partners, LP (Cayman) and its affiliates. From January 2011 to August 2013, he was a managing member of Abacoa Capital Management, LLC, which managed Abacoa Capital Master Fund, Ltd., focused on a Global-Macro investment strategy. From 2005 to 2020, Mr. Herman was affiliated with Arcadia Securities LLC, a New York-based broker-dealer. From 1997 to 2002, he was an investment banker with Burnham Securities, Inc. From 1993 to 1997, he was a managing partner of Kingshill Group, Inc., a merchant banking and financial firm with offices in New York and Tokyo. Mr. Herman has a B.S. from the University at Albany with a major in Political Science and minors in Business and Music. Mr. Herman has many years of experience serving on the boards of private and public companies. He presently sits on the boards and is Audit Chairperson of XS Financial, Inc. (CSE: XS) and SusGlobal Energy Corp. (OTCQB: SNRG).

Email Alerts

News To Your Inbox

For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.